OncologyEducation
@oncologyeducation.bsky.social
Evidence-based, educational resources for the oncology community. Authored exclusively by a leading international faculty of oncology.
September is Gynecologic Cancer Awareness Month.
In Canada, an estimated 8,800 women will be diagnosed with uterine cancer in 2026, making it the most common cancer of the female reproductive system in the country.
Awareness matters: https://bit.ly/4heYtme
#GynecologicCancerAwarenessMonth
In Canada, an estimated 8,800 women will be diagnosed with uterine cancer in 2026, making it the most common cancer of the female reproductive system in the country.
Awareness matters: https://bit.ly/4heYtme
#GynecologicCancerAwarenessMonth
Gynecology - OncologyEducation
www.oncologyeducation.com
September 21, 2026 at 5:50 PM
September is Gynecologic Cancer Awareness Month.
In Canada, an estimated 8,800 women will be diagnosed with uterine cancer in 2026, making it the most common cancer of the female reproductive system in the country.
Awareness matters: https://bit.ly/4heYtme
#GynecologicCancerAwarenessMonth
In Canada, an estimated 8,800 women will be diagnosed with uterine cancer in 2026, making it the most common cancer of the female reproductive system in the country.
Awareness matters: https://bit.ly/4heYtme
#GynecologicCancerAwarenessMonth
Stay current on what’s changing in medical oncology. 🎧
@MedOncNow hosted by Dr. Shaqil Kassam, explores emerging therapies, evolving standards of care and practical insights with leading oncology experts.
🎧 Catch up on the latest episode now: https://bit.ly/4xCUhmB
@MedOncNow hosted by Dr. Shaqil Kassam, explores emerging therapies, evolving standards of care and practical insights with leading oncology experts.
🎧 Catch up on the latest episode now: https://bit.ly/4xCUhmB
Podcast - OncologyEducation
bit.ly
September 18, 2026 at 3:24 PM
Stay current on what’s changing in medical oncology. 🎧
@MedOncNow hosted by Dr. Shaqil Kassam, explores emerging therapies, evolving standards of care and practical insights with leading oncology experts.
🎧 Catch up on the latest episode now: https://bit.ly/4xCUhmB
@MedOncNow hosted by Dr. Shaqil Kassam, explores emerging therapies, evolving standards of care and practical insights with leading oncology experts.
🎧 Catch up on the latest episode now: https://bit.ly/4xCUhmB
🚨 Schedule Update 🚨
The #BestofASCO Toronto Conference 2026 will now run from 7:45 a.m. – 3:00 p.m. EST.
Join us for the latest ASCO® 2026 insights—and attendees will be entered for a chance to win Ray-Ban Meta Wayfarer Smart Glasses 🎁
⏰ Draw: 12:55 p.m.
#ASCO2026 #OncologyEducation #TorontoEvents
The #BestofASCO Toronto Conference 2026 will now run from 7:45 a.m. – 3:00 p.m. EST.
Join us for the latest ASCO® 2026 insights—and attendees will be entered for a chance to win Ray-Ban Meta Wayfarer Smart Glasses 🎁
⏰ Draw: 12:55 p.m.
#ASCO2026 #OncologyEducation #TorontoEvents
June 12, 2026 at 6:36 PM
🚨 Schedule Update 🚨
The #BestofASCO Toronto Conference 2026 will now run from 7:45 a.m. – 3:00 p.m. EST.
Join us for the latest ASCO® 2026 insights—and attendees will be entered for a chance to win Ray-Ban Meta Wayfarer Smart Glasses 🎁
⏰ Draw: 12:55 p.m.
#ASCO2026 #OncologyEducation #TorontoEvents
The #BestofASCO Toronto Conference 2026 will now run from 7:45 a.m. – 3:00 p.m. EST.
Join us for the latest ASCO® 2026 insights—and attendees will be entered for a chance to win Ray-Ban Meta Wayfarer Smart Glasses 🎁
⏰ Draw: 12:55 p.m.
#ASCO2026 #OncologyEducation #TorontoEvents
🎙️ New #MedOncNow Episode!
Dr. Shaqil Kassam sits down with Dr. Howie Lim to discuss perioperative gastric cancer, emerging evidence, and evolving treatment strategies.
Listen now. 🎧
#GastricCancer #Oncology #CancerCare #MedTwitter
Dr. Shaqil Kassam sits down with Dr. Howie Lim to discuss perioperative gastric cancer, emerging evidence, and evolving treatment strategies.
Listen now. 🎧
#GastricCancer #Oncology #CancerCare #MedTwitter
June 11, 2026 at 6:34 PM
🎙️ New #MedOncNow Episode!
Dr. Shaqil Kassam sits down with Dr. Howie Lim to discuss perioperative gastric cancer, emerging evidence, and evolving treatment strategies.
Listen now. 🎧
#GastricCancer #Oncology #CancerCare #MedTwitter
Dr. Shaqil Kassam sits down with Dr. Howie Lim to discuss perioperative gastric cancer, emerging evidence, and evolving treatment strategies.
Listen now. 🎧
#GastricCancer #Oncology #CancerCare #MedTwitter
🚨 Final day at #ASCO2026!
This week we've seen advances in AI, blood-based biomarkers, immunotherapy, and precision oncology—all focused on delivering the right treatment to the right patient at the right time.
Stay tuned for Day 4 highlights. 👇
This week we've seen advances in AI, blood-based biomarkers, immunotherapy, and precision oncology—all focused on delivering the right treatment to the right patient at the right time.
Stay tuned for Day 4 highlights. 👇
June 2, 2026 at 1:37 PM
🚨 Final day at #ASCO2026!
This week we've seen advances in AI, blood-based biomarkers, immunotherapy, and precision oncology—all focused on delivering the right treatment to the right patient at the right time.
Stay tuned for Day 4 highlights. 👇
This week we've seen advances in AI, blood-based biomarkers, immunotherapy, and precision oncology—all focused on delivering the right treatment to the right patient at the right time.
Stay tuned for Day 4 highlights. 👇
🧬 @DrBetofMDPhD shares phase II results of OBX115, an engineered TIL therapy showing a 67% response rate in advanced melanoma, with a favorable safety profile and no need for systemic IL-2.
https://bit.ly/4uPLFbQ
#ASCO2026 #Melanoma
https://bit.ly/4uPLFbQ
#ASCO2026 #Melanoma
ASCO® 2026 Highlights: Presenter Vignette - Allison Betof - OncologyEducation
bit.ly
June 1, 2026 at 11:46 PM
🧬 @DrBetofMDPhD shares phase II results of OBX115, an engineered TIL therapy showing a 67% response rate in advanced melanoma, with a favorable safety profile and no need for systemic IL-2.
https://bit.ly/4uPLFbQ
#ASCO2026 #Melanoma
https://bit.ly/4uPLFbQ
#ASCO2026 #Melanoma
🧬 Dr. Paolo Ciracì presents an AI-powered histopathology biomarker that may help personalize upfront treatment decisions in metastatic colorectal cancer.
https://bit.ly/4obI6dl
https://bit.ly/4obI6dl
ASCO® 2026 Highlights: Presenter Vignette - Paolo Ciracì - OncologyEducation
bit.ly
June 1, 2026 at 11:43 PM
🧬 Dr. Paolo Ciracì presents an AI-powered histopathology biomarker that may help personalize upfront treatment decisions in metastatic colorectal cancer.
https://bit.ly/4obI6dl
https://bit.ly/4obI6dl
🎗️ Dr. Ghassan Abou-Alfa shares results from EMERALD-3, where adding STRIDE + TACE improved PFS to ~13 months versus 8–9 months with TACE alone in intermediate-stage HCC, supporting a potential new standard of care.
https://bit.ly/4usskMV
#ASCO2026
https://bit.ly/4usskMV
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Ghassan Abou-Alfa - OncologyEducation
bit.ly
June 1, 2026 at 11:40 PM
🎗️ Dr. Ghassan Abou-Alfa shares results from EMERALD-3, where adding STRIDE + TACE improved PFS to ~13 months versus 8–9 months with TACE alone in intermediate-stage HCC, supporting a potential new standard of care.
https://bit.ly/4usskMV
#ASCO2026
https://bit.ly/4usskMV
#ASCO2026
🧬 Dr. Elizabeth McDonald discusses research linking GLP-1 agonist use to a 30% lower incidence of breast cancer, highlighting a potential new avenue for cancer prevention.
https://bit.ly/4dGC5lo
#ASCO2026
https://bit.ly/4dGC5lo
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Elizabeth McDonald - OncologyEducation
www.oncologyeducation.com
June 1, 2026 at 11:35 PM
🧬 Dr. Elizabeth McDonald discusses research linking GLP-1 agonist use to a 30% lower incidence of breast cancer, highlighting a potential new avenue for cancer prevention.
https://bit.ly/4dGC5lo
#ASCO2026
https://bit.ly/4dGC5lo
#ASCO2026
🫁 Dr. Jamie Chaft reviews the EA5142 study, where adjuvant nivolumab showed no meaningful DFS benefit after surgery and chemotherapy, reinforcing the role of pre-operative chemoimmunotherapy in NSCLC.
https://bit.ly/3QaAco1
#ASCO2026
https://bit.ly/3QaAco1
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Jamie Chaft - OncologyEducation
bit.ly
June 1, 2026 at 11:34 PM
🫁 Dr. Jamie Chaft reviews the EA5142 study, where adjuvant nivolumab showed no meaningful DFS benefit after surgery and chemotherapy, reinforcing the role of pre-operative chemoimmunotherapy in NSCLC.
https://bit.ly/3QaAco1
#ASCO2026
https://bit.ly/3QaAco1
#ASCO2026
👁️ Dr. Marlana Orloff shares OptimUM-02 findings showing darovasertib plus crizotinib improved outcomes in metastatic uveal melanoma, addressing a major unmet need for HLA-A2 negative patients.
https://bit.ly/4nYgXug
#ASCO2026 #Melanoma
https://bit.ly/4nYgXug
#ASCO2026 #Melanoma
ASCO® 2026 Highlights: Presenter Vignette - Marlana Orloff - OncologyEducation
bit.ly
June 1, 2026 at 11:34 PM
👁️ Dr. Marlana Orloff shares OptimUM-02 findings showing darovasertib plus crizotinib improved outcomes in metastatic uveal melanoma, addressing a major unmet need for HLA-A2 negative patients.
https://bit.ly/4nYgXug
#ASCO2026 #Melanoma
https://bit.ly/4nYgXug
#ASCO2026 #Melanoma
🎗️ Dr. Shilpa Gupta discusses the phase III MAIN-CAV trial, where adding cabozantinib to avelumab maintenance showed no clear benefit in advanced urothelial cancer, while biomarker analyses continue.
https://bit.ly/3PVs6PR
#ASCO2026
https://bit.ly/3PVs6PR
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Shilpa Gupta - OncologyEducation
bit.ly
June 1, 2026 at 11:33 PM
🎗️ Dr. Shilpa Gupta discusses the phase III MAIN-CAV trial, where adding cabozantinib to avelumab maintenance showed no clear benefit in advanced urothelial cancer, while biomarker analyses continue.
https://bit.ly/3PVs6PR
#ASCO2026
https://bit.ly/3PVs6PR
#ASCO2026
📊 Dr. Claudio Vernieri presents PALMARES-2 data showing selected patients with HR+/HER2− advanced breast cancer may benefit from continuing first-line ET + CDK4/6 inhibition beyond progression.
https://bit.ly/4feLNN0
#ASCO2026
https://bit.ly/4feLNN0
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Claudio Vernieri - OncologyEducation
bit.ly
June 1, 2026 at 11:30 PM
📊 Dr. Claudio Vernieri presents PALMARES-2 data showing selected patients with HR+/HER2− advanced breast cancer may benefit from continuing first-line ET + CDK4/6 inhibition beyond progression.
https://bit.ly/4feLNN0
#ASCO2026
https://bit.ly/4feLNN0
#ASCO2026
🎗️ Dr. Lucy Gilbert shares subgroup analyses from the phase III ROSELLA trial, showing relacorilant maintained its survival benefit regardless of prior taxane exposure in platinum-resistant ovarian cancer.
https://bit.ly/3RxsogB
#ASCO2026
https://bit.ly/3RxsogB
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Lucy Gilbert - OncologyEducation
bit.ly
June 1, 2026 at 11:28 PM
🎗️ Dr. Lucy Gilbert shares subgroup analyses from the phase III ROSELLA trial, showing relacorilant maintained its survival benefit regardless of prior taxane exposure in platinum-resistant ovarian cancer.
https://bit.ly/3RxsogB
#ASCO2026
https://bit.ly/3RxsogB
#ASCO2026
🤖 Dr. Paolo Ciracì highlights an AI-powered histopathology biomarker that may help identify which patients with metastatic colorectal cancer benefit most from upfront treatment intensification.
https://bit.ly/4obI6dl
#ASCO2026
https://bit.ly/4obI6dl
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Paolo Ciracì - OncologyEducation
bit.ly
June 1, 2026 at 11:26 PM
🤖 Dr. Paolo Ciracì highlights an AI-powered histopathology biomarker that may help identify which patients with metastatic colorectal cancer benefit most from upfront treatment intensification.
https://bit.ly/4obI6dl
#ASCO2026
https://bit.ly/4obI6dl
#ASCO2026
📈 Dr. Robert Stein discusses the OPTIMA trial, demonstrating that genomic testing can identify many patients with ER+/HER2− early breast cancer who may safely avoid chemotherapy.
https://bit.ly/4u8UD2C
#ASCO2026
https://bit.ly/4u8UD2C
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Robert Stein - OncologyEducation
bit.ly
June 1, 2026 at 11:25 PM
📈 Dr. Robert Stein discusses the OPTIMA trial, demonstrating that genomic testing can identify many patients with ER+/HER2− early breast cancer who may safely avoid chemotherapy.
https://bit.ly/4u8UD2C
#ASCO2026
https://bit.ly/4u8UD2C
#ASCO2026
🔬 Dr. Maggie Banys-Paluchowski presents AXSANA findings showing tumour biology—not the number of involved lymph nodes—is the strongest predictor of axillary response after neoadjuvant therapy.
https://bit.ly/4x1oGM7
#ASCO2026
https://bit.ly/4x1oGM7
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Maggie Banys-Paluchowski - OncologyEducation
bit.ly
June 1, 2026 at 11:25 PM
🔬 Dr. Maggie Banys-Paluchowski presents AXSANA findings showing tumour biology—not the number of involved lymph nodes—is the strongest predictor of axillary response after neoadjuvant therapy.
https://bit.ly/4x1oGM7
#ASCO2026
https://bit.ly/4x1oGM7
#ASCO2026
🧬 Dr. Pavlos Msaouel presents findings supporting EGFR blockade in SMARCB1-deficient renal medullary carcinoma, offering a potential new treatment strategy for this rare disease.
https://bit.ly/4fkHIXG
#ASCO2026
https://bit.ly/4fkHIXG
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Pavlos Msaouel - OncologyEducation
bit.ly
June 1, 2026 at 11:20 PM
🧬 Dr. Pavlos Msaouel presents findings supporting EGFR blockade in SMARCB1-deficient renal medullary carcinoma, offering a potential new treatment strategy for this rare disease.
https://bit.ly/4fkHIXG
#ASCO2026
https://bit.ly/4fkHIXG
#ASCO2026
🥗 Dr. Livia Augustin explores how Mediterranean diet, physical activity, and vitamin D may influence breast cancer recurrence and cardiometabolic health in a multicentre randomized study.
https://bit.ly/4u8Uv38
#ASCO2026
https://bit.ly/4u8Uv38
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Livia Augustin - OncologyEducation
bit.ly
June 1, 2026 at 11:17 PM
🥗 Dr. Livia Augustin explores how Mediterranean diet, physical activity, and vitamin D may influence breast cancer recurrence and cardiometabolic health in a multicentre randomized study.
https://bit.ly/4u8Uv38
#ASCO2026
https://bit.ly/4u8Uv38
#ASCO2026
🤝 Dr. Achim Wöckel reviews the BETTER-CARE trial, evaluating individualized, needs-based follow-up care for patients after primary breast cancer treatment.
https://bit.ly/4ffN5aw
#ASCO2026
https://bit.ly/4ffN5aw
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Achim Wöckel - OncologyEducation
bit.ly
June 1, 2026 at 11:10 PM
🤝 Dr. Achim Wöckel reviews the BETTER-CARE trial, evaluating individualized, needs-based follow-up care for patients after primary breast cancer treatment.
https://bit.ly/4ffN5aw
#ASCO2026
https://bit.ly/4ffN5aw
#ASCO2026
🧬 @DrBetofMDPhD discusses phase II results of OBX-115, an engineered TIL therapy featuring membrane-bound IL-15, showing promising activity in advanced melanoma after immune checkpoint inhibitors.
https://bit.ly/4uPLFbQ
#ASCO2026
https://bit.ly/4uPLFbQ
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Allison Betof - OncologyEducation
bit.ly
June 1, 2026 at 11:05 PM
🧬 @DrBetofMDPhD discusses phase II results of OBX-115, an engineered TIL therapy featuring membrane-bound IL-15, showing promising activity in advanced melanoma after immune checkpoint inhibitors.
https://bit.ly/4uPLFbQ
#ASCO2026
https://bit.ly/4uPLFbQ
#ASCO2026
🎗️ @ATarhiniMDPhD reviews a phase II study of neoadjuvant ipilimumab, nivolumab, and relatlimab in high-risk resectable melanoma, highlighting the continued evolution of combination immunotherapy approaches.
https://bit.ly/4uf1rM9
#ASCO2026
https://bit.ly/4uf1rM9
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Ahmad Tarhini - OncologyEducation
bit.ly
June 1, 2026 at 11:02 PM
🎗️ @ATarhiniMDPhD reviews a phase II study of neoadjuvant ipilimumab, nivolumab, and relatlimab in high-risk resectable melanoma, highlighting the continued evolution of combination immunotherapy approaches.
https://bit.ly/4uf1rM9
#ASCO2026
https://bit.ly/4uf1rM9
#ASCO2026
🧪 @ArndtVogel presents findings from IMbrave251, evaluating atezolizumab-based strategies in advanced hepatocellular carcinoma following prior atezolizumab and bevacizumab treatment.
https://bit.ly/4dREN6h
#ASCO2026
https://bit.ly/4dREN6h
#ASCO2026
ASCO® 2026 Highlights: Presenter Vignette - Arndt Vogel - OncologyEducation
bit.ly
June 1, 2026 at 11:00 PM
🧪 @ArndtVogel presents findings from IMbrave251, evaluating atezolizumab-based strategies in advanced hepatocellular carcinoma following prior atezolizumab and bevacizumab treatment.
https://bit.ly/4dREN6h
#ASCO2026
https://bit.ly/4dREN6h
#ASCO2026
